{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:40Z","timestamp":1793686360292,"version":"4.5.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There is an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) in patients with inflammatory rheumatic diseases (IRD) including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and systemic sclerosis. The mechanism for the development of ASCVD in these conditions has been linked not only to a higher prevalence and undertreatment of traditional cardiovascular (CV) risk factors but importantly to chronic inflammation and a dysregulated immune system which contribute to impaired endothelial and microvascular function, factors that may contribute to accelerated atherosclerosis. Accurate ASCVD risk stratification and optimal risk management remain challenging in this population with many barriers that include lack of validated risk calculators, the remitting and relapsing nature of underlying disease, deleterious effect of medications used to manage rheumatic diseases, multimorbidity, decreased mobility due to joint pain, and lack of clarity about who bears the responsibility of performing CV risk assessment and management (rheumatologist vs. primary care provider vs. cardiologist). Despite recent advances in this field, there remain significant gaps in knowledge regarding the best diagnostic and management approach. The evolving field of Cardio-Rheumatology focuses on optimization of cardiovascular care and research in this patient population through collaboration and coordination of care between rheumatologists, cardiologists, radiologists, and primary care providers. This review aims to provide an overview of current state of knowledge about ASCVD risk stratification in patients with IRD, contributing factors including effect of medications, and review of the current recommendations for cardiovascular risk management in patients with inflammatory disease with a focus on hypertension as a key risk factor.<\/jats:p>","DOI":"10.1093\/ajh\/hpae098","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T09:37:22Z","timestamp":1721986642000},"page":"933-942","source":"Crossref","is-referenced-by-count":9,"title":["Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart"],"prefix":"10.1093","volume":"37","author":[{"given":"Shadi","family":"Akhtari","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Women\u2019s College Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Department of Medicine, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J","family":"Harvey","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Women\u2019s College Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Department of Medicine, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1715","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Women\u2019s College Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Department of Medicine, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"2024111510305889500_CIT0001","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024111510305889500_CIT0002","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0003","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"key":"2024111510305889500_CIT0004","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jacc.2021.02.029","article-title":"Long-term cardiovascular outcomes in systemic lupus erythematosus","volume":"77","author":"Yafasova","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024111510305889500_CIT0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.atherosclerosis.2007.11.013","article-title":"Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis","volume":"198","author":"Ciftci","year":"2008","journal-title":"Atherosclerosis"},{"key":"2024111510305889500_CIT0006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/acr.24108","article-title":"Coronary microvascular dysfunction in rheumatoid arthritis compared to diabetes mellitus and association with all-cause mortality","volume":"73","author":"Liao","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024111510305889500_CIT0007","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"2024111510305889500_CIT0008","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avina-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024111510305889500_CIT0009","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1093\/rheumatology\/keab204","article-title":"Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study","volume":"60","author":"Palomaki","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024111510305889500_CIT0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.20855","article-title":"The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years","volume":"52","author":"Nicola","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024111510305889500_CIT0011","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","article-title":"Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure","volume":"69","author":"Mantel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2024111510305889500_CIT0012","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1756-185X.12820","article-title":"Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"20","author":"Ungprasert","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2024111510305889500_CIT0013","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.20878","article-title":"Cardiovascular death in rheumatoid arthritis: a population-based study","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024111510305889500_CIT0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"2024111510305889500_CIT0015","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/acr.24578","article-title":"Incidence of and risk factors for heart failure in patients with psoriatic disease\u2014a cohort study","volume":"74","author":"Koppikar","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024111510305889500_CIT0016","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3899\/jrheum.170379","article-title":"Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study","volume":"45","author":"Eder","year":"2018","journal-title":"J Rheumatol"},{"key":"2024111510305889500_CIT0017","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.cjca.2022.04.002","article-title":"Statin use for primary cardiovascular disease prevention is low in inflammatory arthritis","volume":"38","author":"Kuriya","year":"2022","journal-title":"Can J Cardiol"},{"key":"2024111510305889500_CIT0018","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3899\/jrheum.190261","article-title":"Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: a systematic review","volume":"47","author":"Colaco","year":"2020","journal-title":"J Rheumatol"},{"key":"2024111510305889500_CIT0019","doi-asserted-by":"crossref","first-page":"e000448","DOI":"10.1136\/lupus-2020-000448","article-title":"Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus","volume":"8","author":"Sivakumaran","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2024111510305889500_CIT0020","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1002\/art.20612","article-title":"Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis","volume":"50","author":"Kremers","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024111510305889500_CIT0021","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0022","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0023","doi-asserted-by":"crossref","first-page":"e0205506","DOI":"10.1371\/journal.pone.0205506","article-title":"Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: an Italian bicentric study","volume":"13","author":"Navarini","year":"2018","journal-title":"PLoS One"},{"key":"2024111510305889500_CIT0024","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/annrheumdis-2014-206879","article-title":"Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms","volume":"75","author":"Arts","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0025","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0026","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2024111510305889500_CIT0027","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"2024111510305889500_CIT0028","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024111510305889500_CIT0029","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-Risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2024111510305889500_CIT0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/heartjnl-2011-300747","article-title":"Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review","volume":"98","author":"Peters","year":"2012","journal-title":"Heart"},{"key":"2024111510305889500_CIT0031","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jacc.2015.08.035","article-title":"10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study)","volume":"66","author":"McClelland","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024111510305889500_CIT0032","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s10067-021-06002-0","article-title":"Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients","volume":"41","author":"Galarza-Delgado","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2024111510305889500_CIT0033","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/art.40925","article-title":"Value of carotid ultrasound in cardiovascular risk stratification in patients with psoriatic disease","volume":"71","author":"Sobchak","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024111510305889500_CIT0034","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/annrheumdis-2012-203101","article-title":"Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study","volume":"73","author":"Corrales","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0035","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/art.30265","article-title":"Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis","volume":"63","author":"Evans","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024111510305889500_CIT0036","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10741-019-09779-0","article-title":"Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases","volume":"24","author":"Mavrogeni","year":"2019","journal-title":"Heart Fail Rev"},{"key":"2024111510305889500_CIT0037","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","article-title":"The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review","volume":"49","author":"Westlake","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2024111510305889500_CIT0038","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"2024111510305889500_CIT0039","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2012.12.027","article-title":"Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study","volume":"43","author":"Guin","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2024111510305889500_CIT0040","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard-2023-224185","article-title":"Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study","volume":"82","author":"So","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0041","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0042","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2012-203137","article-title":"Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study","volume":"73","author":"Lindhardsen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0043","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2024111510305889500_CIT0044","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2024111510305889500_CIT0045","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2024111510305889500_CIT0046","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/0961203317734922","article-title":"Antimalarial-induced cardiomyopathy: a systematic review of the literature","volume":"27","author":"Tselios","year":"2018","journal-title":"Lupus"},{"key":"2024111510305889500_CIT0047","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/jch.13364","article-title":"Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC\/AHA Hypertension Guideline","volume":"20","author":"Ritchey","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2024111510305889500_CIT0048","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024111510305889500_CIT0049","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamacardio.2016.0218","article-title":"Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews","volume":"1","author":"Karmali","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2024111510305889500_CIT0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0167-5273(15)31026-3","article-title":"Global burden of CVD: focus on secondary prevention of cardiovascular disease","volume":"201","author":"Bansilal","year":"2015","journal-title":"Int J Cardiol"},{"key":"2024111510305889500_CIT0051","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"Han","year":"2006","journal-title":"J Rheumatol"},{"key":"2024111510305889500_CIT0052","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/ar3473","article-title":"Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2024111510305889500_CIT0053","first-page":"493","article-title":"Cardiovascular risk factor screening in systemic lupus erythematosus","volume":"30","author":"Al-Herz","year":"2003","journal-title":"J Rheumatol"},{"key":"2024111510305889500_CIT0054","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3899\/jrheum.101132","article-title":"Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus","volume":"38","author":"Sabio","year":"2011","journal-title":"J Rheumatol"},{"key":"2024111510305889500_CIT0055","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/rheumatology\/kem169","article-title":"Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis","volume":"46","author":"Panoulas","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2024111510305889500_CIT0056","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.atherosclerosis.2007.01.004","article-title":"Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis","volume":"196","author":"Chung","year":"2008","journal-title":"Atherosclerosis"},{"key":"2024111510305889500_CIT0057","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00296-016-3464-9","article-title":"The metabolic profile in early rheumatoid arthritis: a high prevalence of metabolic obesity","volume":"37","author":"Muller","year":"2017","journal-title":"Rheumatol Int"},{"key":"2024111510305889500_CIT0058","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1002\/art.20636","article-title":"Cardiovascular risk factors in women with and without rheumatoid arthritis","volume":"50","author":"Solomon","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024111510305889500_CIT0059","doi-asserted-by":"crossref","first-page":"e000267","DOI":"10.1136\/rmdopen-2016-000267","article-title":"Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants","volume":"2","author":"Siebert","year":"2016","journal-title":"RMD Open"},{"key":"2024111510305889500_CIT0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/acr.23094","article-title":"Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study","volume":"69","author":"Jafri","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024111510305889500_CIT0061","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1007\/s10067-016-3362-2","article-title":"Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study","volume":"35","author":"Ahmed","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2024111510305889500_CIT0062","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3899\/jrheum.141359","article-title":"Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study","volume":"43","author":"Haque","year":"2016","journal-title":"J Rheumatol"},{"key":"2024111510305889500_CIT0063","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1002\/art.11296","article-title":"Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study","volume":"48","author":"Bruce","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2024111510305889500_CIT0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/747946","article-title":"Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy","volume":"2010","author":"Shanmugam","year":"2010","journal-title":"Int J Rheumatol"},{"key":"2024111510305889500_CIT0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semarthrit.2013.07.007","article-title":"Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal","volume":"43","author":"Tselios","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2024111510305889500_CIT0066","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijcard.2018.06.111","article-title":"Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases","volume":"274","author":"Ikdahl","year":"2019","journal-title":"Int J Cardiol"},{"key":"2024111510305889500_CIT0067","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41927-020-0112-5","article-title":"Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis","volume":"4","author":"Navarro-Millan","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2024111510305889500_CIT0068","first-page":"526","article-title":"Appropriate cardiovascular disease risk assessment in systemic lupus erythematosus may be lacking in rheumatology practice","volume":"36","author":"Esmaeilbeigi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2024111510305889500_CIT0069","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/BOR.0000000000000318","article-title":"Environmental exposures and the development of systemic lupus erythematosus","volume":"28","author":"Barbhaiya","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2024111510305889500_CIT0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/cei.12372","article-title":"Emerging role of leptin in rheumatoid arthritis","volume":"177","author":"Tian","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2024111510305889500_CIT0071","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1161\/CIRCULATIONAHA.107.741645","article-title":"Leptin and cardiovascular disease: response to therapeutic interventions","volume":"117","author":"Koh","year":"2008","journal-title":"Circulation"},{"key":"2024111510305889500_CIT0072","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrcardio.2017.118","article-title":"Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases","volume":"15","author":"Bartoloni","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2024111510305889500_CIT0073","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0074","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.HYP.0000258106.74139.25","article-title":"Cardiovascular effects of the cyclooxygenase inhibitors","volume":"49","author":"White","year":"2007","journal-title":"Hypertension"},{"key":"2024111510305889500_CIT0075","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(08)60137-3","article-title":"COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs","volume":"371","author":"Warner","year":"2008","journal-title":"Lancet"},{"key":"2024111510305889500_CIT0076","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","article-title":"Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis","volume":"121","author":"Johnson","year":"1994","journal-title":"Ann Intern Med"},{"key":"2024111510305889500_CIT0077","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1185\/030079907X219553","article-title":"Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension","volume":"23","author":"Morrison","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2024111510305889500_CIT0078","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archinte.1993.00410040045007","article-title":"A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure","volume":"153","author":"Pope","year":"1993","journal-title":"Arch Intern Med"},{"key":"2024111510305889500_CIT0079","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/eurheartj\/ehx508","article-title":"Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial","volume":"38","author":"Ruschitzka","year":"2017","journal-title":"Eur Heart J"},{"key":"2024111510305889500_CIT0080","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","article-title":"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2024111510305889500_CIT0081","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","article-title":"Mechanism of action for leflunomide in rheumatoid arthritis","volume":"93","author":"Fox","year":"1999","journal-title":"Clin Immunol"},{"key":"2024111510305889500_CIT0082","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/rheumatology\/ken159","article-title":"Hypertension in rheumatoid arthritis","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2024111510305889500_CIT0083","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1136\/heartjnl-2015-307838","article-title":"Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders","volume":"102","author":"Agca","year":"2016","journal-title":"Heart"},{"key":"2024111510305889500_CIT0084","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/jhh.2013.80","article-title":"Infliximab, a TNF-alpha inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients","volume":"28","author":"Yoshida","year":"2014","journal-title":"J Hum Hypertens"},{"key":"2024111510305889500_CIT0085","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/annrheumdis-2019-216764","article-title":"Impact of the new American College of Cardiology\/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus","volume":"79","author":"Tselios","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024111510305889500_CIT0086","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2024111510305889500_CIT0087","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/CIRCULATIONAHA.107.734384","article-title":"Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis","volume":"117","author":"Flammer","year":"2008","journal-title":"Circulation"},{"key":"2024111510305889500_CIT0088","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(86)91271-7","article-title":"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics","volume":"1","author":"Wong","year":"1986","journal-title":"Lancet"},{"key":"2024111510305889500_CIT0089","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00004872-200205000-00037","article-title":"Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study","volume":"20","author":"Fogari","year":"2002","journal-title":"J Hypertens"},{"key":"2024111510305889500_CIT0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0895-7061(94)00164-7","article-title":"Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine","volume":"8","author":"Klassen","year":"1995","journal-title":"Am J Hypertens"},{"key":"2024111510305889500_CIT0091","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1097\/00004872-199312050-00148","article-title":"Interaction of indomethacin with felodipine and enalapril","volume":"11","author":"Morgan","year":"1993","journal-title":"J Hypertens Suppl"},{"key":"2024111510305889500_CIT0092","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1111\/bcp.15330","article-title":"Psoriasis risk after beta-blocker exposure: description of a pharmacovigilance signal","volume":"88","author":"Azzouz","year":"2022","journal-title":"Br J Clin Pharmacol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpae098\/58777831\/hpae098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/37\/12\/933\/60409297\/hpae098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/37\/12\/933\/60409297\/hpae098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T10:31:47Z","timestamp":1731666707000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/37\/12\/933\/7721253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":92,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,7,26]]},"published-print":{"date-parts":[[2024,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpae098","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,26]]}}}